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Background and aims: Saffron is a spice with preventive and curative effects. This study aimed to review
the toxicity of saffron extract and its constituents on normal and cancer cells.
Methods: We searched the PubMed, Science direct, SID and Magiran databases up to November 2015
using the following key words: toxicity, saffron, crocin, crocetin, safranal, cancer. Finally, 73 English and 5
Persian articles were selected to be recruited to be reviewed.
Results: Saffron has selective toxicity against cancer cells, through inhibition of RNA and DNA synthesis
and increasing apoptosis. Crocin has been considered as the most important anticancer agent of saffron
that plays a role in gene expression and apoptosis in cancer cells. Crocetin has an inhibitory effect on the
cancer cells growth that may be due to reduced synthesis of DNA, RNA and protein in neoplastic cells,
RNA polymerase II inhibition, and interaction with histone H1 and H1-DNA structures. Saffron and its
crocin and crocetin have also shown anticancer and cancer-preventive effects in animal models of cancer.
Safranal also has shown antitumor activity with low toxicity. On the other hand, the lethal dose of 50%
(LD50) for the saffron and its constituents against normal cells can be very high.
Conclusion: In conclusion, emerging evidence suggests that saffron extract and its crocin, crocetin and
safranal have a selective toxicity effects against cancer cells and also may have cancer preventive
functions. However, Saffron and its constituent's toxicity against normal cells is negligible and they are
even non-toxic in oral administration.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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Cancer remains as a major leading cause of mortality world-
wide. It has been reported that more than 8 million people are
diagnosed with cancer each year. Moreover, 1,530,000 new cases of
cancer and nearly 570,000 cancer deaths occurred in United State in
2010 [1]. Various types of cancers have different prevalence in
different communities [2]. Changes in cancer patterns due to
immigration have decreased the role of genetics in the observed
differences among communities [3]. Studies showed that majority
of cancers may be prevented by changes in lifestyle and environ-
ment, including following a healthy diet [4]. Recently, chemopre-
vention is considered as an effective treatment for cancer. In this
regard, there is a considerable attention to the roles of herbs and
spices in tumor growth inhibition and cancer progression [5].
Dried Stigma of saffron (Crocus sativus L.) is considered as the
most expensive traditional spice byweight all over theworld [1e3].
It has been estimated that Iran accounts for about 76% of the total
world saffron production annually [4,5]. Saffron has been used as a
stomach pain soother, antispasmodic, digestion aid, renal colic
pains reliever, antidepressant, and appetizer agent in Islamic-
Persian traditional medicine [6,7]. The stigma is the most used part
of the saffron. The observed beneﬁcial effects of the dried stigma
are contributed to three main secondary metabolites including
soluble crocin (mono-glycosyl or di-glycosyl polyenesters) which is
responsible for saffron special color, picrocrocin (mono-terpene
glycosideprecursorof safranal) which is responsible for saffron
bitter taste, and safranal which is responsible for its special odor.
Saffron contains a considerable amount of lipophilic carotenoids
and ﬂavonoids, as well as trace amounts of B1 and B2 vitamins
[8e17]. Conducted researches have contributed beneﬁcial effects of
saffron to its antioxidant and anti-inﬂammatory properties, which
may be related to saffron active constituents [18,19].
Although, many studies have investigated the effect of saffron
and its active constituents in the prevention and treatment of
cancer, so far, the exact mechanism of action has not been cleared
yet [20e25]. to the aim of the present study was to review the
literature on anticancer and toxic effects of saffron and its con-
stituents as a chemo-preventive herb and propose mechanisms of
action.2. Material and methods
We identiﬁed published studies using MEDLINE (PubMed) and
Science direct, SID and Magiran databases by following keywords
provided fromMESH: 'saffron', 'crocin', 'crocetin', 'safranal', 'saffron
constituent', 'colchicum', 'cytotoxicity', 'toxicity', 'cancer',
'neoplasm', 'tumor', 'tumoricidal effect', and 'detrimental effect' We
included all studies from inception up to November 2015 with
language restriction (English and Persian, only). A total of 276 pa-
pers were found through the preliminary searching, among which
20 papers were in Persian. The inclusion criteria namely were
interventional studies in human populations, in vitro and in vivo
animal studies. However, we could not ﬁnd any clinical trial. The
exclusion criteria were articles in which the active components of
saffron were obtained from a source other than saffron, articles in
which the used saffron were belonged to a very special race otherthan the conventional saffron, and ﬁnally articles in which saffron
was used either as a component of a mix herbal medicine or as an
ingredient of a drug. The quality of the articles was assessed by
Strengthening the Reporting of Observational Studies in Epidmi-
ology (STROBE) statement [28]. The search protocol is shown in
Fig. 1. Finally, 73 English and 5 Persian articles were reviewed.
3. Results
3.1. In vitro studies
In vitro studies on toxicity effects of saffron and its constituents
on tumor cells are shown in the Table 1.
3.1.1. Saffron
In an in vitro study which evaluated the effect of ethanol extract
of saffron on macromolecules synthesis in three cell layers,
including cells taken from lung tumors, normal lung ﬁbroblasts and
virus induced transformed ﬁbroblast cells, it has found that ma-
lignant cells aremore sensitive to the inhibitory effects of saffron on
the synthesis of RNA and DNA compared to the normal cells [29].
The inhibition of RNA and DNA synthesis is regarded as one of the
main mechanisms of anti-tumor and anti-carcinogenic effects of
saffron [17]. In another study, ethanol extract of saffron was incu-
bated on the Hela (human epithelial cell of epitheloid carcinoma)
and Hep G2 (epithelial like hepatocellular carcinoma cells) cell
layers in different doses (200e2000 mgr/mL) for about 24, 48 and
72 h. Inhibitory concentration 50% (IC50) against Hela and Hep G2
cell layers were 800 and 950 mgr/mL after 48 h, respectively. Data
indicated that apoptosis plays a major role in the toxicity effects of
saffron, although, it is not the only determining factor. Therefore,
other functions of saffron should be taken into account. Since the
ROS (reactive oxygen species) did not change during the study
period, it seems that ROS did not have a role in these effects. In this
study, signiﬁcant inhibition of colony formation as well as DNA and
RNA synthesis (50% inhibition) was seen at doses of 100e150 mgr/
mL, while, no effect regarding inhibition of protein synthesis was
found, even at high doses [33]. Several other mechanisms for anti-
cancer effects of saffron particularly reactions with nucleic acid
chain and free radicals, and carotenoids interaction with topo-
isomerase II were also reported [17,26]. It is plausible that syner-
gistic effects of saffron phytochemicals increase their anti-cancer
effects [34]. Tavakkol-Afshari et al. reported that alcoholic extract of
saffron induced selective cytotoxicity against Hep G2 and Hela
cells; however, did not have any toxic effects on normal ﬁbroblast
cells in rats [35]. In another study, the effects of different doses of
the saffron extract (100, 200, 400 and 800 mgr/mL) were investi-
gated on human alveolar carcinoma cells (cells A549) for three
days. The study indicated that the percentage of apoptotic cells
increased in a dose dependentmanner with the presence of saffron.
The researchers also observed apoptosis in the presence of caspase-
dependent pathways stimulation. Human lung ﬁbroblast cells as
control cells were less affected by the pathway. The study
demonstrated that anti-cancer effects of saffron can be partly
attributed to the inhibition of cell proliferation and stimulation of
apoptosis through caspase-dependent pathways [36]. However, in
another study it has been reported that the saffron extract in doses
Fig. 1. Diagram of related studies search and extraction.
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In vitro studies on saffron induced non-speciﬁc proliferation of
lymphocytes in the presence of T cell mitogen phytohaemag-
glutinin [30], indicated that antitumor activity of saffron may be
mediated immunologically. However, the constituents of saffron
(ginsenosides and cannabinoid) could not reverse multi drug
resistance in lymphoma cells [38]. Two other studies have sepa-
rated a new bioactive substance from the saffron stem [40,39].
Lethal dose 50% (LD50) for the substance against HeLa cells was
9 mgr/mL. The toxicity of this substance was also studied in the
humanmalignant cell layers, a non-malignant cell layer, blood cells,
and hair follicles. Calculated LD50 for tumor cells was 7 to 22 mgr/mL, and 100 mgr/mL for ﬁbroblasts normal cells. On the other hand,
it seems that this substance toxicity is 8 times higher in tumor cells
compared with the non-tumor types [33].
In conclusion, it seems that saffron may have selective toxicity
against cancer cells through various mechanisms such as inhibition
of RNA and DNA synthesis and increasing apoptosis, and protein
synthesis. So, it seems that some gene pathways related to cell
apoptosis induction and proliferation inhibition is the major anti-
tumor mechanism of saffron.
3.1.2. Crocin
Spanish researchers investigated the effects of four constituents
Table 1
Saffron toxicity against cancer cells at in vitro.
Study Target cells Intervention Results
Abdullaev F et al. 1992 [29] Lung tumor cells, normal lung ﬁbroblasts and
transformed ﬁbroblasts
Saffron alcoholic extract Saffron inhibited the growth of malignant cells by
blocking the synthesis of RNA and DNA
Abdullaev F et al. 1992 [33] Human embryonic epithelial cells of the cervix
(Hela) and liver carcinoma cells (Hep G2)
Saffron alcoholic extract,
and crocetin like substances
Saffron and crocetin like substances inhibited the
growth of tumor cells by apoptotic and non-apoptotic
mechanisms
Tavakkol-Afshar et al.2008 [35] Hepatocellular carcinoma epithelial-like cells
(Hep G2) and human cervical carcinoma cells
Saffron alcoholic extract Saffron had selective cytotoxicity against tumor cells
Samarghandian et al. 2013 [36] Human alveolar carcinoma cells (cells A549) Saffron aqueous extract Apoptotic malignant cells percentage increased dose
dependently in the presence of saffron
Abdullaev Fet al. 1992 [33] HeLa cells and human malignant cell layer Isolated substance from
saffron
ID50 against Hela cells was 9mgr/ml, and 7 to 22 mgr/ml
against malignant cells
Escribano J et al. 1996 [41] HeLa cervical carcinoma cells Crocin, crocetin,
picrocrocin, and safranal
All the constituents inhibited cancer cells growth. The
effect of crocin was more considerable.
Molnar J et al. 1999 [38] Human cells infected with adenovirus Crocin and di glucosyl
crocetin
Crocin and di glucosyl crocetin had inhibitory effects on
primary expression of tumor antigen at adenovirus
infected cells
Garc-Olmo DC et al. 1999 [44] HT-29 cells and DHD/k12 (adenocarcinoma
cells in rat and human colon carcinoma cells)
Crocin Crocin exhibited strong selective cytotoxicity against
HT-29 and DHD/k12 cells
Noureini et al. 2012 [45] Hep G2 cells Crocin Crocin exhibited selective cytotoxicity against cancer
cells
Aung Hal et al. 2007 [46] Three layers of colorectal cancer cells (HCT-116,
SW-480 and HT-29)
Crocin Crocin signiﬁcantly inhibited these three cells layers
with a dose dependent manner
Mehri et al. 2012 [47] PC12 Cells Crocin Crocin had neuro protective effect on acrylamide
induced cytotoxicity in PC12 cells with a dose
dependent manner
Abdullaev FI et al. 1994 [35] HeLa cells, lung cancer cells modiﬁed fetal lung
ﬁbroblast
Crocetin Crocetin inhibited cancer cells growth through dose
dependent inhibition of protein and nucleic acid
synthesis
Jagadeeswaran R et al. 2000 [51] Human rhabdomyosarcoma cells Crocetin Crocetin had selective cytotoxicity against human
rhabdomyosarcoma compared with cisplatin
Chryssanthi DG et al. 2007 [52] MDA-MB-231 and MCF-7 breast cancer cells Crocetin and its analogs Crocetin and its analogs dose dependently inhibited
breast cancer cells growth
Mousavi et al., 2009 [53] MCF-7 cells Crocetin Crocetin had a pro-apoptotic effect on cancer cells
Tarantilis P et al. 1994 [31],
Morjani H et al. 1990 [43]
Promyelocytic leukemia cells (HL60) and
human myelogenous leukemia cells (K562)
Crocetin Crocetin had cytotoxic effects against leukemia cells
Wang C-J et al., 1991 [55] Fibroblast cells C3H10T1/2 Crocetin Pretreatment with crocetin signiﬁcantly inhibited
aﬂatoxin induced cytotoxicity in ﬁbroblast cells
Abdullaev F 1992 [33] A549 (lung carcinoma) and VA13 (SV-40
transformed fetal lung ﬁbroblasts) Cells
Crocetin Crocetin had inhibitory effects on nucleic acid synthesis
and lung cancer cells colony formation
Dhar A 2008 [59] MIA-PaCa-2, BxPC3, Capan1 and Ascpc1
pancreatic cancer cells
Crocetin Crocetin had anti-tumorigenic effects on pancreatic
cancer cells
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cells of cervix carcinoma. Crocin showed the strongest inhibitory
effect. The inhibitory effects of ethanol extract of saffron on in vitro
growth of the HeLa cells (ID50 ¼ 2.3 mg/ml) and apoptosis inhibi-
tion were mainly attributed to crocin (ID50 ¼ 3 mM). However,
picrocrocin and safranal had minor effects (ID50 was 3 and 0.8 mM,
respectively). Moreover, crocetin did not show any cytotoxicity ef-
fect in the study. Therefore, crocin may be considered as the most
important anti-cancer constituents of saffron [41]. Since, crocin is
the glycated form of saffron constituents, it seems that glucose
added to the crocin structuremay increase its antitumor properties.
It may be due to glucose ability to interact with DNA structure.
Another study found that saffron isolated crocin and dimethyl
crocetin did not have mutagenic effects [42]. Likewise, Molnar et al.
reported that crocin and di glucosyl crocetin have inhibitory effects
at different doses on the primary expression of tumor antigens in
the adenovirus infected cells [38]. It also seems that sugars play a
major role in the potential toxicity effect of the crocin, since cro-
cetin (which is deglycosilated derivative of crocin) could not inhibit
cell growth, even at high doses [43]. In another study, crocin was
regarded as the most important anti-cancer constituent of saffron
[17]. Garc-Olmo et al. reported that crocin exhibited potent cyto-
toxic effects against HT-29 and DHD/k12 cells (adenocarcinoma
cells of rats and human colon) with a LD50 of 0.4 and 1 mM,
respectively. Crocin also signiﬁcantly decreased cytoplasm andwide cytoplasmic vacuole-like areas of the cells [44]. This low LD50
and the observed morphogenic changes in colon tumor cell layers
may indicate that crocin can be more toxic against gastrointestinal
cancer cells than other tumors cells. Microscopic studies have
demonstrated that vacuolated areas and reduction in the size of the
cells and the pyknotic nuclei of crocin treated HeLa cells may be
attributed to stimulation of programmed cell death [43,44]. A study
which investigated the crocin effects on Hep G2 cells, reported that
after 48 h, crocin exhibited cytotoxicity effects on these cells at dose
of 3 mg/mL. Telomerase activity and catalytic section of telomerase
gene expression, decreased by 51% and 60% with a dose-dependent
manner, respectively. Since, the transcription of the telomerase
gene is higher in cancer cells compared to the normal ones, it seems
that crocin has selective effects on cancer cells [45]. Telomerase
concentration did not change during the study, therefore, crocin
probably has interact only with telomerase gene area and may in-
crease the enzyme stability rather than protein synthesis. In the
same line with this data, another study found that saffron derived
crocin signiﬁcantly inhibited the growth of three layers of colo-
rectal cancer cells (HCT-116, SW-480 and HT-29) with a dose-
dependent manner [46] Dose dependent neuro-protective effect
of crocin (at the doses of 10, 20 and 50 mmol) against cytotoxicity of
acrylamide in PC12 cells has been attributed to its antioxidant
properties [47]. Other possible mechanisms of this effect can be
inhibition of protein aggregation and ﬁbrillar formation [48].
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cancer constituent of saffron. It seems that crocin exhibits this ef-
fect through changes in gene expression and induction of apoptosis
in cancer cells.
3.1.3. Crocetin
While some studies have not considered crocetin as an anti-
cancer constituent of saffron [43,41], other studies have demon-
strated anticancer effects of it [56e49,46]. In one study, inhibitory
effects of saffron isolated crocetin on the synthesis of nucleic acid
and protein in three human malignant cell layers, including HeLa
cells, lung adenocarcinoma, and embryonic deformed lung ﬁbro-
blast cells, have been investigated. Crocetin inhibited protein and
nucleic acid synthesis dose dependently, but had no effect on col-
ony formation [32]. Other studies have also shown growth inhibi-
tion of the cancer cells by dimethyl crocetin, crocetin, and crocin at
doses of 0.8 and 2 mM for 50% inhibition (ID50) [43,31]. Some other
studies have demonstrated that dimethyl crocetin and crocin had
toxic effects on different cell layers (DLA, EAC, S-180, L1210 leuke-
mia and P388 leukemia) and human stem cells isolated from sur-
gical samples (Osteosarcoma, ﬁbrosarcoma and ovarian
carcinoma). Several studies have indicated that crocetin can
signiﬁcantly inhibit the nucleic acids synthesis, and also, dimethyl
crocetin can inhibit DNA-protein interactions (e.g. topoisomerase
II) which are crucial for DNA synthesis [49,30]. Furthermore, some
studies have reported the toxic effects of crocetin against a non-
solid tumor isolated cell layer, different layers of tumor cells, and
human stem cells (derived from surgical samples) [50,31]. In
another study it has been found that crocetin at doses of 5e20 mg/
ml exhibited selective cytotoxic effects against human rhabdo-
myosarcoma cells and less deteriorative effects on normal cells
compared with Cispltin [51]. The effects of crocetin on some types
of cancers are explained below:
1. Breast cancer: Chryssanthi et al. reported that crocetin and its
analogs inhibited breast cancer cells proliferation. In this study,
a dose-dependent inhibition of MDA-MB-231 and MCF breast
cancer cells proliferation was observed in the presence of cro-
cetin. This effect was independent of the estrogen receptors
function [52]. Hence, the antitumor mechanism of crocetin is
independent from hormone regulation. Another study also
investigated the pro-apoptotic effects of crocetin onMCF-7 cells,
indicating that crocetin leads to induction of a caspase-
dependent pathway through elevation of the BAX protein
expression [53].
2) Cervices cancer: It has been reported that crocetin like com-
ponents of saffron may cause signiﬁcant reduction in the colony
formation and DNA and RNA synthesis at doses of 1,200 mg/mL
in Hela cells. Crocetin inhibits DNA-dependent RNA polymerase
II and RNA synthesis [35]. UV spectroscopy showed an interac-
tion between crocetin and tRNA. Accordingly, it seems that
crocetin may have binding activity at the molecular level [54].
3) Leukemia: Two studies have found that crocetin at low doses,
even 0.8 mg, can exhibit cytotoxic effects against promyelocytic
leukemia (HL60) and human myelogenous leukemia (K562)
cells [43,31]. Crocetin cytotoxicity in other cell leukemia layers
(L1210 and P388) has also been reported [43]. Very potent anti-
leukemia properties of crocetin may be related to its polyesters
that may act as an antigen for leukemic cells.
4) Liver cancer: Pre-treatment with crocetin in aﬂatoxin B1 (AFB1)
activated ﬁbroblasts C3H10T1/2 cells, signiﬁcantly inhibited
cytotoxicity and DNA-adduct formation [55]. This protective
effect is probably due to the increase in cytosolic glutathione
(GSH) following elevated GSH-S-transferase (GST) formation.
According to one study, the inhibitory effect of crocetin ongenotoxicity of benzo (a) pyrin and neoplastic formation in
C3H10T1/2 cells is due to the increased activity of GSH and
reduced formation of benzo (a) Pyrin- DNA adducts [57]. The
study also indicated that crocetin inhibits ROS induced malon-
dialdehyde (MDA) formation, produced by xanthine oxidase
(XO), and thus, inhibits the oxidative damages [58]. Therefore,
crocetin may induce protective effects through scavenging free
radicals following neoplastic transformation [58,57].
5) Lung cancer: It has been shown that crocetin (at doses of 100 to
150 mgr/mL) exhibits inhibitory effects on nucleic acid synthesis
and colony formation of A549 (lung carcinoma) and VA13
(transformed SV-40 of fetal lung ﬁbroblasts) cells [33].
6) Pancreatic cancer: A study in 2009 for the ﬁrst time investi-
gated anti-cancer potential of crocetin on pancreatic cancer
using different pancreatic cancer cells as well as a Xeno-
graftathymic mice model. Crocetin (at doses of 50e200 mmol/L
for 72 h), inhibited proliferation of MIA-PaCa-2, BxPC3, Capan1,
and Ascpc1 cells. The study also indicated that DNA synthesis
was inhibited in pancreatic cancer cells in the presence of cro-
cetin. Moreover, it has been suggested that a reduction in the
imbalance between anti-apoptotic (Bcl-2) and pro-apoptotic
(Bax) proteins may be the main mechanism of crocetin anti-
tumor formation activity [59]. Recent data demonstrated that
crocetin along with low-doses of Paclitaxel or Cisplatin can
inhibit proliferation and stimulate apoptosis of pancreatic can-
cer cells [60]. Therefore, crocetin can act safely along with the
common chemotherapy drugs.
Based on the aforementioned ﬁndings, crocetin inhibits the
growth of some types of cancer cells. This effect may be due to the
reduced synthesis of DNA, RNA and protein. Crocetin also inhibits
RNA polymerase II in neoplastic cells [32]. Similarly, it has been
reported that crocetin interacts with the structure of histone H1
and the H1-DNA, which suggests that anti-cancer mechanisms of
crocetin may be different, and epigenetic effects can also be one of
them [61]. Crocetin inhibits protein and nucleic acid synthesis and
then interact with some protein cascades.3.1.4. Safranal
Safranal is the major coloring constituent of saffron [13].
Samarghandian et al. study has investigated antitumor activity of
safranal in different doses (0, 10, 15, 20, 50 mg/ml) in cultured
neuroblastoma cells. Safranal dose dependently inhibited cell
proliferation and induced cell apoptosis with an IC50 of 11.1 and
23.3 mg/ml after 24 and 48 h, respectively [62]. Moreover,
Malaekeh-Nikouei et al. study has shown dose dependent anti-
tumor activity of safranal (0.01e3 mM) against Hela andMCF7 cells
[63]. It seems that apoptosis induction is the most important
antitumor mechanism of safranal. Safranal can be also considered
as the most antitumor saffron constituent against Hela cell layer
tumor [63]. Another study by Samarghandian and Shabestari found
dose dependent antitumor activity of safranal (5, 10, 15, 20 mg/ml)
in a prostate cancer cell layer. Apoptotic effect of safranal is
also expressed in this study, that even approved by DNA analysis
[64].
According to the mentioned studies, safranal exhibits tumor-
ocidal activity even at low doses. Because of dose dependent effects
and lowdoses tumorocidal activity, it can be considered as themost
potent toxic constituent of saffron with selective toxicity.3.2. In vivo studies-animal
Animal in vivo studies regarding the effects of saffron and its
constituents against cancer are shown in the Table 2.
Table 2
Saffron toxicity against cancer in in vivo animal studies.
Study Animal Intervention Dose Time Results
Salomi M et al. 1991 [49] Mice Saffron extract 100 mg/kg 12 weeks Saffron extract inhibited onset
and progression of induced skin
tumors and delay papilloma
onset in rats
Bathaie SZ et al. 2013 [69] Rat Saffron aqueous extract 100, 150, and 175 mg/kg 50 days Saffron inhibited cancer
progression dose dependently
El Daly E et al. 1997 [68] Rat Saffron extract þ cystein 50 mg/kg 5 days Saffron extract along with
cysteine signiﬁcantly reduced
cisplatin toxicity
Premkumar K et al. 2001 [73] Swiss
albino mice
Saffron aqueous extract 20, 40, and 80 mg/kg 5 days pretreatment Saffron signiﬁcantly reduced
genotoxicity of anti-cancer
drugs
Garc-Olmo DC et al. 1999 [43] Rat Crocin e crocetin Crocin at a dose of 400 mg/kge crocetin
at doses of 50e200 mmol/liter
13 weeks Crocin treatment signiﬁcantly
increased survival of rats with
colorectal tumor. Crocetin
reduced tumor growth in
female rats.
Hariri et al. 2011 [76] Rat Crocin - safranal Crocin at doses of 50, 100,
and 200 mg/kg e safranal at
doses of 0.25, 0.05, and 0.1 mg/kg
4 weeks Crocin and safranal reduced
Diazinon cytotoxicity in rat
blood, but did not inhibit
genotoxicity
Wang CJ et al. 1996 [77] Rat Crocetin 60 and 120 mmol 15 min Crocetin inhibited induced skin
cancer in rat
Wang C-J et al. 1991 [56] Rat Crocetin 2 to 6 mg/kg 3 days preteatment Crocetin protected liver against
aﬂatoxin induced
carcinogenicity
Wang C-J et al. 1991 [78] Rat Crocetin 0.1 mg 45 weeks Crocetin signiﬁcantly inhibited
aﬂatoxin induced hepatotoxic
ulcers
Magesh V et al. 2006 [79] Swiss
albino mice
Crocetin 20 mg/kg 4 weeks pretreatment Crocetin had anti-tumor effect
against lung cancer
Magesh V et al. 2009 [80] Swiss
albino mice
Crocetin 50 mg/kg 18 weeks Crocetin inhibited lung cancer
cells proliferation
Dhar A et al. 2009 [59] Athymic
mice
Crocetin 4 mg/kg 30 days Crocetin had anti-tumor effect
against pancreatic cancer
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Salomi et al. have conducted a 12-weeks study to assess the
effect of saffron extract on induced cancer in albino rats. Two to
seven papilloma was observed in the 90% of rats in the control
group, while, the saffron group (100 mg/kg) had only 0.26 to 1
papilloma. Saffron extract inhibited formation and progression of
induced skin tumors in rats and also delayed papilloma attack [49].
Oral intake of the same dosage extract induced sarcoma in soft
tissues of rats, and limited tumor formation [49,42]. In one study
the chemopreventive effects of the carotenoids rich extract have
been related to lipid peroxidation, antioxidants and detoxiﬁcation
systems regulation [65]. Previous studies have shown that anti-
tumor effects of saffron are more considerable at oral than intra-
venous receiving. Therefore, it seems that some structural trans-
formationsmay occur during saffron ingestion. Moreover, liposome
encapsulated saffron is more effective at oral administration. The
liposome encapsulated saffron signiﬁcantly inhibited implanted
tumor cells growth in rats [66]. Oral administration with alcoholic
extract of saffron (200 mg/kg) increased Lifetime of the sarcoma
cells in transplanted albino rats [30,67]. Furthermore, oral admin-
istration of the extract increased serum b-carotene and vitamin A
levels in the animals [68]. Therefore, it seems that saffron carot-
enoids may have vitamin A precursor function and their anti-
cancer effects may be related to this function, as some studies
have regarded В-carotene (a precursor of vitamin A) as an antiox-
idant [31]. Moreover, B-carotene transformation to vitamin A may
be the major cause of higher effectiveness of oral administration.
Another study investigated the effects of saffron aqueous extract on
induced gastric cancer in rats. Aqueous extract (100, 150, and
175 mg/kg) inhibited cancer progression after 50 days in a dose-dependent manner. Hence, 20% of rats treated with higher doses
of the extract were completely normal and none of the rats in the
extract group was affected by adenoma at the end of the study. In
this study, increased apoptosis and proliferation conﬁrmed the pro-
apoptotic effect of saffron. In addition, saffron renormalized serum
levels of enzymes and antioxidants after induction of cancer [69].
The antitumor activity of saffron against gastric cancer at such low
doses may indicate local and systemic effects on the gastrointes-
tinal cells.
Although, the mentioned studies have found anti-carcinogenic
effects of saffron, a majority of in vivo studies have investigated
the effects of saffron constituents rather than saffron extracts [34].
On the other hand, different studies have found that saffron
extract (at a low dose such as 2 mg/kg) increased lifetime and
reduced the drug side effects in Cisplatin treated mice [70e72].
Likewise, pre-treatment with aqueous extract of saffron (at doses of
20, 40 and 80 mg/kg) in Swiss albino mice, signiﬁcantly reduced
genotoxicity of anticancer drugs [73]. Animals treatment with
cysteine (20 mg/kg) and saffron extract (50 mg/kg) signiﬁcantly
reduced the Cisplatin induced toxicity [68]. In the study by
Mohajeri et al. alcoholic extract of saffron at a dose of 80 mg/kg for
30 days, reduced Rifampin induced hepatotoxicity in rats, which
was similar to the silymarin effects [74].
In conclusion, saffron also exhibits anti-cancer effects in animal
models of cancer which may be attributed to its antioxidant and
pro-apoptotic actions in the cancer cells. Oral administration of
saffron is more effective, that may be attributed to its B-carotene
precursor properties. Saffron also induced antioxidant enzymes.
Moreover, it seems that saffron may also reduce the toxic effects of
cancer drugs, although, the mechanism has not been cleared yet.
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One study investigated the effects of long-term treatment with
crocin (400 mg/kg) on tumor growth and lifetime of adenocarci-
noma cell subcutaneous injection of induced colorectal tumor in
rats. Crocin treatment signiﬁcantly increased survival of the ani-
mals and reduced tumor growth, specially in females [44]. This
selective effect on the females suggested that crocin performance
may partly be related to hormonal factors. Another study has also
indicated that crocin reduced Diazinon cytotoxicity in rat blood
samples, but did not inhibit genotoxicity [75]. In Naghizadeh et al.
study, crocin at doses of 100, 200 and 400 mg/kg attenuated acute
renal toxicity induced by Cisplatin [76].
3.2.3. Crocetin
A study on the frog embryo demonstrated that saffron isolated
crocetin was effective in the treatment of some cancers which are
treatable with all-trans retinoic acid (ATRA). The study suggested
that crocetin may be a safer alternative therapy for treatment of
ATRA sensitive cancers in pregnancy [50]. Dhar et al. have shown
that crocetin exhibits anti-tumorigenic effect in pancreatic cancer
both in vitro and in vivo [59]. Similarly, Wang et al. indicated that
crocetin at doses of 60 and 120 mmol can inhibit induced skin cancer
through inhibiting protein kinase C activity by 50% and 66%,
respectively in rats [77]. Garcia-Olmo et al. also reported that sup-
plementation with crocetin (at the doses of 50e200 mol/L) slowed
tumor growth in female rats, but not signiﬁcantly in male rats [44].
Accordingly, it seems that at least one of the female hormones may
play a role in this effect. A study has reported that pre-treatment
with crocetin (2e6 mg/kg) protected liver against damages
caused by AFB1 and inhibited formation of AFB1-DNA adducts by
increasing liver GSH and activating GST and glutathione peroxidase
(GSH-Px) in rats [56]. In another study, signiﬁcant suppression of
AFB1 induced hepatotoxic ulcers has observed due to the reduction
in the activity of aspartate amino transferase (AST), alanine amino
transferase (ALT), alkaline phosphatase and gamma glutamyl trans-
peptidase (GGT) after pretreatment with crocetin (1.0 mg) in rats
[78]. An in vivo study reported that crocetin (20 mg/kg) has anti-
tumor activity against a lung cancer animal model. Crocetin exhibits
these actions through scavenging free radicals and increasing ac-
tivity of drug metabolizing enzymes. The study also found that
crocetin inhibited lipid peroxidation and increased GST, GSH-Px,
catalase, and superoxide dismutase (SOD) activities. Similarly, cro-
cetin reduced carcinogen related marker enzymes such as aryl hy-
drocarbon hydroxylase (AHH), lactate dehydrogenase (LDH), GGT,
adenosine deaminase (ADA) and 50 nucleotidase in lung tissue after
Benzo (a) Pyrin induction [79]. Magesh et al. study showed that
50 mg/kg crocetin inhibited lung cancer cells proliferation. The
study strongly suggested that the protective effect of crocetin on
lung carcinogenesis induced by benzo (a) Pyrin in Swiss albinomice
was most likely due to the inhibitory effects on polyamine synthesis
and glycoproteins changes [80]. In an animal model study, crocetin
(at the dose of 4 mg/kg) had anti-tumorigenic effects on pancreatic
cancer through inhibiting the proliferation (by inhibiting phos-
phorylation and expression of EGFR) in athymic mice [59]. There-
fore, crocetin may intervene with gene expression and
phosphorylation at higher doses. In the same line with these ﬁnd-
ings, another study found that crocetin (600 mg/kg) delayed onset
of skin tumors, tumor formation in skin induced by Dimethyl Benz
[a] Anthracene (DMBA), and its progression by castor oil in Swiss
Webster rats [81]. In a similar study, antitumor activity of crocetin
was observed in DMBA and castor oil induced skin cancer in hairless
rats [82]. Moreover, a study in mice has reported that crocetin at a
dose of 50 mg/kg attenuated the bladder toxicity of cyclophos-
phamide anti-cancer compounds without altering their antitumor
activity [71].In conclusion, crocetin may exhibit anti-cancer and cancer-
preventive effects even in the presence of cancer inducing factors.
These effects can be attributed to the antioxidant potential and
internal enzymes regulation by crocetin. Crocetin also regulate liver
enzymes.
3.2.4. Safranal
The DNA protective effect of safranal that observed in in vitro
studies, has also previously found in Hosseindzadeh and Sadeghnia
study. The protective effect was dose dependently [83]. According
to the study, we can assume DNA migration inhibition along with
apoptosis induction as the safranal protective mechanisms.
3.3. Toxicity against normal cells
Compelling evidence suggests that saffron toxicity is quite low
[17,30,67,84,85]. In animal studies, calculated LD50 for oral intake of
saffron is 20.7gr/kg [17]. Studies have reported controversial results
regarding the harmful effects of saffron. Some studies have re-
ported that the injection of 1.2 to 2gr/ABW2 saffron may cause
nausea, vomiting, diarrhea and bleeding [15], while, other studies
even with a high dose of 4gr per day for several days did not
observe adverse effect, even in the pregnant women. However, all
of these studies have conducted in Germany and it is not clear
whether the used saffron is a common type or nativewild saffron of
Germany [15,27]. Furthermore, it seems that some toxicities such as
gastrointestinal symptoms and bleeding only occur with injection.
According to a study, high doses of saffron (more than 10 gr) may
stimulate absorption and induce previously reported side effects
including loss of appetite, insomnia, nausea, vomiting and dizziness
[15]. One study also reported an allergy case to saffron [86].
Determined ID50 of saffron in these studies is high (20gr/kg),
therefore, researchers have considered saffron as a safe herb for
human consumption [84]. In the in vivo studies in animals, a very
low or even zero toxicity of saffron and its constituents is reported
[30,67,85]. A study has investigated the toxicity of safranal in daily
intakes on 2nd and 21thdays in rats and mice, respectively. LD50 for
intraperitoneal injection has determined as 1.48 ml/kg in male
mice, 1.88 ml/kg in female mice, and 1.50 ml/kg in male rats. LD50
for Oral intake was 21.42 ml/kg in male mice, 11.42 ml/kg in female
mice, and 5.53 ml/kg in male rats. According to the results, safranal
toxicity in mice and rats at intraperitoneal injection is low, and it is
non-toxic at oral administration. Moreover, safranal did not cause
death at oral doses of 0.1, 0.25, and 0.5 mg/kg for 21 days in rats
[87]. Ziaee et al. study has found that saffron and safranal co-
treatment may inhibit safranal alone treatment toxicity. However,
safranal toxicity was only limited to triglyceride, blood urea nitro-
gen, and alanine amino transferase. Saffron was not toxic in this
study even at a dose of 10 mg/kg [88]. However, a recent study by
Riahi-Zanjani et al. could not ﬁnd hematologic, histopathologic or
immune system toxic effects by safranal in mice. It seems that
safranal doses used in this study were higher (0.1, 0.5 and 1 mg/kg)
compared to the similar studies [89]. Hence, it seems that despite
public belief about safranal toxicity that considers safranal as the
most toxic constituent of saffron, available studies have reported
low LD50 for safranal [88,89].
Moreover, Hariri et al. study have shown that crocin at doses of
50, 100 and 200 mg/kg and safranal at doses of 0.025, 0.05 and 0.1
have reduced diazinon toxicities include hematologic changes [90].
In Hariri et al. study safranal at doses of 0.025, 0.05 and 0.1 mg/kg
and crocin at doses of 50, 100 and 200 mg/kg have moderated
hematologic toxicities of diazinon, but not by genotoxicity inhibi-
tion [76].
A study found that oral intake as well as intraperitoneal injec-
tion of crocin (3gr/kg) did not cause death within 2 days in mice
Table 3
Saffron toxicity against normal cells.
Study Study condition Intervention Administration Dose
Abdullaev FI et al. 2002 [48] In vivo- animal saffron oral 20.7 gr/kg The dose was equivalent to LD50 and
was non-toxic
Schmidt M et al. 2007 [15] In vivo- animal saffron injection 1.2 to 2 gr/ABWa Nausea, vomiting, diarrhea, and bleeding
were observed.
Melnyk JP et al. 2010 [27] In vivo- human saffron oral 4 gr/day Non-toxic
Hosseinzadeh
et al. 2013 [87]
In vivo e rats and
mice
safranal Oral- injection 1.48 ml/kg in male mice,
1.88 ml/kg in female mice, 1.50 ml/kg
in male rat intraperitoneal, 21.42 ml/kg
in male mice, 11.42 ml/kg in female mice,
and 5.53 ml/kg in male rat in oral intake
Non-toxic
Modaghegh
et al. 2008 [92]
In vivo- human saffron oral 200 to 400 mg/day Biochemical and hematologic
parameters were changed in the normal
ranges in healthy adults
a Actual Body Weight.
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matocrit, hemoglobin, and erythrocytes, while, they did not cause
signiﬁcant damage in any body organs [41]. Saffron pill altered
biochemical and hematological parameters in high doses
(200e400 mg/day) in healthy adults; however, these changes were
in the normal ranges and were clinically non-considerable [92]. A
study found that crocin did not cause death or major organ dam-
ages at pharmacologic doses [91]. However, a Persian study by
Mohajeri et al. has shown that saffron extract in very high intra-
peritoneal injected doses (0.35, 0.7 and 1.05 g/kg) induced anemia
and hepato-renal toxicity in rats [93]. Furthermore, it has been
shown that pregnant women should not consume saffron for
medical purposes, since it can cause uterus contraction [26]
(Table 3). Bahmani et al. study has determined saffron toxicity in
different doses (500, 100 and 2000 mg/kg/day) in newborn mice.
LD50 for 3 weeks oral administration was determined as 556 mg/
kg. Histopathology tests have found only slight changes in mice
kidney. Moreover, 21 days oral administration of saffron to lactating
mothers only increase blood urea nitrogen [94]. Although, saffron
toxicity is very low in this study, hematologic changes indicate that
pregnant and lactating women should avoid at least from con-
sumption of high doses of saffron.
In conclusion, due to the high LD50 of saffron and its constituents
in normal cells, it seems that their toxic effect against non-cancer
cells on the body is reasonably low. Moreover, it seems that some
toxicities only occur with injection of saffron and its constituents.
Furthermore, safranal is low toxic, and even, may reduce toxic ef-
fects of some drugs.4. Discussion
According to the aforementioned ﬁndings, saffron and its con-
stituents appropriately act against cancer formation and exhibit
selective toxicity against tumors. In addition, saffron and its con-
stituents can inhibit anti-cancer drugs toxicity. However, this effect
occurs with high doses of saffron. Although, anti-cancer mecha-
nisms of saffron and its constituents have not been cleared yet,
many probable mechanisms have been proposed. For instance,
saffron may directly target DNA and regulate gene expression.
Although, RNA synthesis inhibition has been observed, protein
synthesis did not change signiﬁcantly in various studies. There-
ofore, it seems that some gene pathways related to cell apoptosis
induction and proliferation inhibition such as caspase pathway
moderation is the major antitumor mechanism of saffron.
Bathaie et al. has shown that saffron carotenoids (crocin, cro-
cetin, and dimethyl crocetin) directly link to the DNA small groovesand consequently, cause changes in the DNA structure. Saffron may
also stimulate apoptosis in tumor cells [69]. It seems that apoptosis
stimulation by saffron plays an important role in human liver (Hep
G2) and human cervical (Hela) carcinoma cells death [35]. More-
over, saffron oral administration maybe more effective than intra-
peritoneal injection that can be attributed to its B-carotene
precursor properties. Saffron also induced antioxidant enzymes.
Anti-cancer effect of crocetin may be due to reduced synthesis of
DNA, RNA and protein. Potent antitumor activity of crocin may be
due to sugar in its structure that may interact with DNA bases to
regulate some pathways such as telomerase pathway. Crocetin also
inhibits RNA polymerase II in neoplastic cells. It also has been found
that crocetin interact with the structure of histone H1 and H1-DNA.
These ﬁndings suggest that anticancer mechanisms of crocetin are
different, and epigenetic mechanisms can also be one of to them.
Antioxidant and anti-inﬂammatory properties of saffron and its
constituents may be regarded as other anti-cancer mechanisms.
Interestingly, in addition to the vitamin A precursor activity of
saffron, crocetin may play a role similar to retinoic acid. Since
crocetin and saffron can regulate serum levels of liver enzymes in
the fatty liver disease, a major worldwide problem, it can be
considered as a suitable clue for future studies.
Safranal also induced antitumor activity with low toxicity.
Although, some studies have found safranal toxicities at high doses
[88,89]. Apoptosis induction is the most mentioned antitumor
mechanism of safranal. Safranal exhibits tumorocidal activity even
at low doses. Because of dose dependent effects and low doses
tumorocidal activity, it maybe considered as the most potent toxic
constituent of saffron with selective toxicity.
In addition, the impact of saffron and its constituents on the
gene expression and enzymes regulation are the recently discussed
mechanisms. However, there are rare clinical trials regarding anti-
cancer effects of saffron. Moreover, further studies are warranted to
determine the effective dose of saffron and conclusive mechanisms
of it. Besides, the absence of human studies has made it difﬁcult to
generalize the results of laboratory and animal studies to humans
and also, to determine the best dose for human consumption,
hence, clinical trials are recommended for future researches.
Furthermore, it seems that anti-cancer effects of saffron constitu-
ents synergistically increase, and thus, saffron extract may exhibit
strongest anticancer activity compared to its constituents, alone.
Interestingly, it seems that saffron toxicity is selective and target
only cancer cells. Since, according to the international classiﬁcation,
LD50 between 1 to 5gr/kg is practically considered as low toxicity
and more than 5 gr/kg as non-toxic [95,96], saffron and its con-
stituents, at least can be regarded as “with low toxicity” substances.
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symptoms and bleeding only occur with injection of saffron and its
constituents. Hence, they can be considered as “non-toxic” at oral
intakes [76,88e90]. However, Vulnerable groups such as pregnant
and lactating women should avoid high doses consumption of
safranal, and saffron.
On the other hand, the actual amount of saffron used in daily
dietary intakes is very lower than doses used in the studies that
reported side effects (including nausea, vomiting, diarrhea,
bleeding, changes in hematologic and hepato-renal toxicity)
[15,41,92,93]. Moreover, observed beneﬁcial effects of saffron are in
low doses which are fairly similar to doses used in daily dietary
intakes.
5. Conclusion
Saffron and its constituents have cancer preventive effects and
selective toxicity against cancer cells, while, they do not have toxic
effects against normal cells. However, the results of conducted
studies are inconclusive, and further researches are needed.
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